Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry
Ryan C. Ungaro, Erica J. Brenner, Manasi Agrawal, et al.
Gastroenterology (2021) Vol. 162, Iss. 1, pp. 316-319.e5
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Paracellular permeability and tight junction regulation in gut health and disease
Arie Horowitz, Sandra D. Chánez-Paredes, Xenia Haest, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 417-432
Open Access | Times Cited: 304
Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy
Gian Marco Leone, Katia Mangano, Maria Cristina Petralia, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1630-1630
Open Access | Times Cited: 82
Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian Nationwide Analysis
Stephanie Coward, Eric I. Benchimol, Çharles N. Bernstein, et al.
The American Journal of Gastroenterology (2024) Vol. 119, Iss. 8, pp. 1563-1570
Open Access | Times Cited: 19
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Jan Marsal, Manuel Barreiro‐de Acosta, Irina Blumenstein, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 50
Cytokine Storm-Induced Thyroid Dysfunction in COVID-19: Insights into Pathogenesis and Therapeutic Approaches
Ali Attiq, Sheryar Afzal, Habibah A. Wahab, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 4215-4240
Open Access | Times Cited: 6
Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease
Trevor L. Schell, Keith L. Knutson, Sumona Saha, et al.
Inflammatory Bowel Diseases (2022) Vol. 28, Iss. 11, pp. 1781-1786
Open Access | Times Cited: 27
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic
Simeng Lin, Louis Ho Shing Lau, Neil Chanchlani, et al.
Gut (2022) Vol. 71, Iss. 7, pp. 1426-1439
Open Access | Times Cited: 25
XBB.1.5‐Adapted COVID‐19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS‐CoV‐2 JN.1 Variant in Patients With Inflammatory Bowel Disease
Simon Woelfel, Joel Dütschler, Daniel Junker, et al.
Alimentary Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 5
Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease
Erica J. Brenner, Kimberly N. Weaver, Xian Zhang, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 7, pp. 1475-1486.e4
Closed Access | Times Cited: 4
Lower Expression of SARS-CoV-2 Host Cell Entry Genes in the Intestinal Mucosa of IBD Patients With Quiescent or Mildly Active Disease
Laura Francesca Pisani, Guglielmo Albertini Petroni, Gabriela A. N. Crespi, et al.
Inflammatory Bowel Diseases (2025)
Closed Access
Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination
Freddy Caldera, Francis A. Farraye, Brian M. Necela, et al.
Inflammatory Bowel Diseases (2022) Vol. 29, Iss. 8, pp. 1202-1209
Open Access | Times Cited: 18
Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey
Hiroshi Nakase, Kohei Wagatsuma, Masanori Nojima, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 3, pp. 205-216
Open Access | Times Cited: 8
Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease
Filipa Bordalo Ferreira, Maria Ana Rafael, Lúcia Coimbra, et al.
Vaccine (2023) Vol. 41, Iss. 26, pp. 3862-3871
Open Access | Times Cited: 8
Immunosuppressants exert differential effects on pan‐coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir
Yining Wang, Pengfei Li, Marla Lavrijsen, et al.
United European Gastroenterology Journal (2023) Vol. 11, Iss. 5, pp. 431-447
Open Access | Times Cited: 7
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.
Trevor L. Schell, Freddy Caldera
PubMed (2024) Vol. 20, Iss. 2, pp. 88-97
Closed Access | Times Cited: 2
Risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune‐suppressive drugs: A nationwide cohort study of US Veterans
Sonia T. Anand, Austin D. Vo, Jennifer La, et al.
Transplant Infectious Disease (2023) Vol. 26, Iss. 1
Closed Access | Times Cited: 5
Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Laura Sahyoun, Jonathan Fetene, Chandler McMillan, et al.
Digestive Diseases and Sciences (2024) Vol. 69, Iss. 5, pp. 1654-1660
Closed Access | Times Cited: 1
Update des Addendums zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch-entzündlichen Darmerkrankungen in Bezug auf COVID-19 (Version 2.0)
Carsten Schmidt, Andreas Stallmach, Andreas Sturm, et al.
Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 04, pp. 517-534
Closed Access | Times Cited: 1
COVID-19 vaccination safety and associated health care utilization among adults with inflammatory bowel disease – a population-based self-controlled case series analysis
Jennifer J. Lee, Sasha Bernatsky, Eric I. Benchimol, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases
Rupert W. Leong, Anthony Sakiris, Arteen Arzivian, et al.
Alimentary Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 1
Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID‐19 pandemic: the PREPARE‐IBD multicentre cohort study
Aamir Saifuddin, Alexandra Kent, Shameer Mehta, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 10, pp. 1460-1474
Open Access | Times Cited: 6
The Effects of the COVID Pandemic on Patients with IBD: Lessons Learned and Future Directions
Eva Zhang, Britt Christensen, Finlay Macrae, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 23, pp. 7002-7002
Open Access | Times Cited: 6
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
Judith Wellens, Matthew Edmans, Uri Obolski, et al.
Gut (2021) Vol. 71, Iss. 9, pp. 1919.2-1922
Open Access | Times Cited: 8
Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study
Yen-Ling Peng, Chung-Hsin Chang, Shu‐Chen Wei, et al.
Journal of the Formosan Medical Association (2023) Vol. 122, Iss. 10, pp. 1042-1049
Open Access | Times Cited: 3
Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: data of a national study (ESCAPE-IBD)
Mariabeatrice Principi, Fabio Salvatore Macaluso, Alessia Todeschini, et al.
European Journal of Gastroenterology & Hepatology (2023) Vol. 35, Iss. 6, pp. 629-634
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top